Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,485 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,566 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07572136 | Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) | recruiting | Phase 1 | 57 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07574541 | Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance | not yet recruiting | Phase 2 | 52 | National Cancer Institute (NCI)NIH |
| 1 |
| Sep 29, 2026 |
| clinicaltrials |
| NCT07578571 | A Phase 1 Study of IM-1617 in Participants With Advanced Cancer | recruiting | Phase 1 | 175 | Immunome, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07583810 | Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma | recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07597070 | Universal Immunization to Fortify Immunotherapy Efficacy and Response(UNIFIER) | not yet recruiting | Phase 2 | 500 | University of FloridaOTHER | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07603375 | Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma(TNT Esophagus) | recruiting | Phase 2 | 60 | Duke UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07605416 | Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial | recruiting | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07619534 | Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases | recruiting | — | 139 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07632014 | CAYA Cancer Prospective Cohort Study | recruiting | — | 6,000 | Resonance, Inc.OTHER | 5 | Sep 29, 2026 | clinicaltrials |
| NCT07635420 | Comparing Intraoperative Indocyanine Green Fluorescence Imaging With Standard Clinical Assessment for Flap Perfusion in Head and Neck Reconstruction (VISION Trial)(VISION) | recruiting | Phase 4 | 244 | Region SkaneOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07659795 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer(TARGET-D 203) | recruiting | Phase 2 | 150 | Verastem, Inc.INDUSTRY | 2 | Sep 29, 2026 | clinicaltrials |
| NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07671092 | Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC | recruiting | Early Phase 1 | 40 | RayzeBio, Inc.INDUSTRY | 2 | Sep 29, 2026 | clinicaltrials |
| NCT07671417 | Imaging Study in Metastatic Clear Cell RCC. | recruiting | Early Phase 1 | 10 | RayzeBio, Inc.INDUSTRY | 2 | Sep 29, 2026 | clinicaltrials |
| NCT07686380 | IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy | recruiting | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07705035 | DBC-664 in Adult Patients With Solid Tumors | recruiting | Phase 1 | 210 | Duboce Biopharmaceuticals, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07706179 | Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer | not yet recruiting | Phase 2 | 10 | University of Wisconsin, MadisonOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07707895 | DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers | not yet recruiting | Phase 1 / Phase 2 | 60 | Boehringer IngelheimINDUSTRY | 11 | Sep 29, 2026 | clinicaltrials |
| NCT07715903 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy | not yet recruiting | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07725172 | Radiation Therapy and Thymus Function in Young Women With Breast Cancer | recruiting | — | 125 | Duke UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07755176 | Patient-reported Outcomes Following Percutaneous Ablation of Desmoid Tumors | enrolling by invitation | — | 30 | Mayo ClinicOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07756840 | Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP) | not yet recruiting | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07766187 | Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma(CODAH) | not yet recruiting | Phase 2 | 12 | University of Wisconsin, MadisonOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07770802 | Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer | recruiting | Phase 1 | 15 | Hangzhou Huasai Biomedicine Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07796373 | Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor | not yet recruiting | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07809659 | CanRisk-Based Ovarian Cancer Risk Assessment Versus Standard Practice (DISARM CSA)(DISARM CSA) | recruiting | N/A | 2,130 | Instituto Portugues Oncologia de Lisboa Francisco GentilOTHER | 4 | Sep 29, 2026 | clinicaltrials |
| NCT07823907 | Ultrasound-Guided Microwave Ablation for Breast Fibroadenoma: Safety and Cosmetic Outcomes(MWA-FA) | not yet recruiting | N/A | 40 | Al-Azhar UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07830342 | A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer | recruiting | Phase 1 | 24 | Hangzhou Huasai Biomedicine Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07845617 | Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma | recruiting | — | 10 | AdventHealthOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07845669 | Effects of Synbiotic Supplementation on Gastrointestinal Symptoms, Appetite, and Nutritional Recovery in Patients After Autologous Bone Marrow Transplant | not yet recruiting | N/A | 40 | Alexandria UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07845786 | Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)(STELLAR-202) | not yet recruiting | Phase 2 | 60 | ExelixisINDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07845877 | An Intervention to Reduce Sedentary Behavior and Promote Physical Activity in Colorectal Cancer Chemotherapy | not yet recruiting | N/A | 40 | Yonsei UniversityOTHER | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07845916 | Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer(QS-NSCLC) | not yet recruiting | Phase 2 | 12 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07845994 | SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years(SEMAFORCRANIO) | not yet recruiting | Phase 3 | 50 | University Hospital, AngersOTHER_GOV | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07846046 | Endoscopic (EID) Versus Surgical (TAMIS) Local Excision for Early Stage Rectal Cancer(ENSURE) | not yet recruiting | N/A | 246 | Amsterdam UMC, location VUmcOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07846267 | Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma(CASTLE-ZS-05) | not yet recruiting | Phase 2 | 56 | Fudan UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07846358 | This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.(GFH276X1203) | not yet recruiting | Phase 1 / Phase 2 | 84 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07846592 | Real-time Fluorescence Microscopy for Intraoperative Assessment of Prostate Biopsy Cores (FLASH)(FLASH) | not yet recruiting | — | 450 | Shanghai East HospitalOTHER | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07847060 | Hypofractionated Radiotherapy in Older Adults With Head and Neck Squamous Cell Carcinoma | not yet recruiting | N/A | 60 | Assiut UniversityOTHER | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07847138 | The Effect of Music on Anxiety and Caregiver Burden in Family Caregivers of Patients With Lung Cancer | completed | N/A | 50 | Izmir Bakircay UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07847216 | Multicenter Prospective Study Protocol for Validating Surgical Quality Standards in D3 Lymphadenectomy for Oncological Right Hemicolectomy(D3L) | not yet recruiting | — | 120 | Fundació d'investigació Sanitària de les Illes BalearsOTHER_GOV | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07847268 | A First-in-Human Study of ¹⁷⁷Lu-HX02 in Sarcoma Patients | completed | — | 9 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07847385 | Tractography-Guided Nerve-Sparing in Prostate Cancer(PRO-TRACT) | recruiting | N/A | 23 | Massimo ValerioOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07847398 | Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.(EMMENEO-TN) | not yet recruiting | N/A | 50 | Centre Antoine LacassagneOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07847671 | Fecal Microbiota Transplantation With QL1706 Plus Bevacizumab for Advanced HCC | not yet recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07847710 | Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial(H-FROG) | recruiting | Phase 2 | 81 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
Data updated 24 hours agoSource updated Sep 29, 2026source: clinicaltrials